Shionogi initiates phase II study of cancer peptide vaccine in-licensed from OncoTherapy Science Feb. 6, 2014
Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center licenses anticancer MAb to Novartis Jan. 31, 2014
Patient recruitment begins in phase I trial of Ribological's personalized anticancer vaccine Jan. 29, 2014
RSS